Phase 2 N=21 Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: MTD of Ultratrace Iobenguane I 131 — 8 mCi/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=39 Preoperative Alpha Blockade for Pheochromocytoma
Pheochromocytoma · Paraganglioma
Primary: Hemodynamic Instability — 14; 13 percentage of total operative time — p=.56
Phase 2 N=50 A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Pheochromocytoma · Paraganglioma
Primary: Number of Patients With Complete (CR), Partial (PR), or Minor (MR) Response and Without Progressive Disease — 28 Participants
Phase 2 N=20 Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Locally Advanced Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma · Metastatic Paraganglioma
Primary: Objective Response Rate — 25 percentage of participants
Phase 2 N=25 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
Phase 2 N=3 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Malignant Adrenal Gland Pheochromocytoma · Malignant Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma
Primary: Confirmed Tumor Response Rate — 1.0 participants
Phase 2 N=14 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
Phase 2 N=50 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Phase 2 N=18 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
N/A N=4 Anti-3-[18F]FACBC Imaging of Parathyroid Adenomas
Parathyroid Disease
Primary: Detection Rate of Parathyroid Adenomas of Anti-3-[18F]FACBC Modality — 80 percentage of adenomas detected
Phase 2 N=39 Sunitinib in Refractory Adrenocortical Carcinoma
Adrenocortical Carcinoma
Primary: Assessment of Clinical Benefit Due to Treatment With Sunitinib — 5 Participants
Phase 2 N=30 Phase 2 Study of ONC201 in Neuroendocrine Tumors
Recurrent Neuroendocrine Tumor · Metastatic Neuroendocrine Tumor
Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants
Phase 2 N=13 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Phase 3 N=18 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Adrenal Tumors
Primary: Increase in Catecholamine
Phase 2 N=11 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Phase 2 N=35 Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 3 N=98 18F-Fluorocholine for the Detection of Parathyroid Adenomas
Hyperparathyroidism, Primary
Primary: Proportion of True Positives for the Overall Detection of the Abnormal Parathyroid Adenoma — 0.75 proportion of participants
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 3 N=137 A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Phase 3 N=304 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Carcinoma, Adrenal Cortical
Primary: Overall Survival — 108; 124 participants
Phase 3 N=78 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Phase 2 N=15 Calcium Channel Blockade in Primary Aldosteronism
Primary Aldosteronism · Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Primary: Change in 24-hour Urinary Aldosterone Excretion Rate — 0.21 mcg/24h — p=0.96
Early Phase 1 N=9 Adrenergic System in Islet Transplantation
Type1diabetes · Hypoglycemia · Hypoglycemia Unawareness
Primary: C-PEPTIDE Suppression During Hyperinsulinemia Euglycemia. — 0.51; 0.56; 0.59 ng/mL
Phase 2 N=44 Pazopanib as Single Agent in Advanced NETs
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Phase 1 N=32 High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicity as a Measure of Tolerability — 0; 0 participants with DLT
Phase 4 N=8 Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism
Mild Hypercortisolism
Primary: A1C Level — 6.2; 6.1375; 6.125 percentage of red blood cells
Phase 2 N=29 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Pancreatic Alpha Cell Carcinoma · Pancreatic Beta Islet Cell Carcinoma · Pancreatic Delta Cell Carcinoma
Primary: Determine the Maximum Tolerated Dose (MTD) of Temozolomide in Combination With 400 mg Pazopanib in Patients With Advanced Pancreatic Neuroendocrine Tumor (PNET) in Phase…
Phase 2 N=36 Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Phase 2 N=51 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Gastrin-Producing Neuroendocrine Tumor · Lung Carcinoid Tumor · Metastatic Digestive System Neuroendocrine Tumor G1
Primary: Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 6; 14; 21 participants